Targeting mTOR in Pancreatic Ductal Adenocarcinoma

Targeting mTOR in Pancreatic Ductal Adenocarcinoma

Treatment options for advanced pancreatic ductal adenocarcinoma (PDAC) are limited, however, new therapies targeting specific tumor-related molecular characteristics may help certain patient cohorts. Emerging preclinical data has shown that inhibition of mechanistic target of rapamycin (mTOR) in spe...

Full description

Bibliographic Details
Main Authors: Sentia eIriana, Shahzad eAhmed, Jun eGong, Alagappan Anand Annamalai, Richard eTuli, Andrew Eugene Hendifar
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-04-01
Series:Frontiers in Oncology
Subjects:
Clinical Trials as Topic
preclinical
KRAS
mTOR
Pancreatic Ductal Adenocarcinoma
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00099/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00099/full

Similar Items